GlassScriptPhysician profile
Lisa Larkin
NPI 1679562839
$275,664.81
in general payments reported to CMS, 2019-2025
52 companies · $69K in 2025
The $69K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $25K · 2021: $19K · 2022: $31K · 2023: $47K · 2024: $35K · 2025: $69K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Honoraria: $18K · Travel and Lodging: $14K · Consulting Fee: $14K · Food and Beverage: $9,053 · Grant: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,341.00 |
| Honoraria | $18,120.00 |
| Travel and Lodging | $13,769.84 |
| Consulting Fee | $13,734.50 |
| Food and Beverage | $9,053.25 |
| Grant | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $73,542.46 | 2022-2025 | |
| Astellas Pharma US INC | $65,954.86 | 2020-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $25,864.15 | 2019-2022 | |
| Amgen INC. | $18,323.47 | 2019-2024 | Repatha, Prolia, Evenity |
| Pfizer INC. | $17,449.93 | 2019-2025 | |
| Amag Pharmaceuticals, INC. | $17,112.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16,205.08 | 2022-2025 | |
| Abbvie INC. | $9,502.59 | 2021-2025 | |
| Scynexis, INC. | $6,847.43 | 2022 | |
| Myovant Sciences INC. | $6,075.00 | 2022 | |
| Genetesis, INC. | $6,000.00 | 2021 | |
| Allergan, INC. | $5,630.56 | 2019-2021 | |
| Radius Health, INC. | $3,047.14 | 2020-2025 | Tymlos |
| Novo Nordisk INC | $860.46 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Agile Therapeutics, INC. | $425.00 | 2023 | Twirla |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $265.17 | 2022 | |
| Caris Mpi, INC. | $232.79 | 2025 | Mi Cancer Seek |
| Corcept Therapeutics | $206.74 | 2024-2025 | Korlym |
| Lilly USA, LLC | $199.26 | 2019-2025 | Mounjaro, Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $195.66 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.31 | 2021-2025 | Xifaxan |
| Dexcom, INC. | $147.42 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $126.30 | 2019-2024 | |
| Qol Medical, LLC | $122.25 | 2021-2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $116.70 | 2023 | Linzess |
| Cleerly, INC. | $108.90 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Teva Pharmaceuticals USA, INC. | $86.10 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $85.13 | 2024-2025 | Airsupra |
| Sumitomo Pharma America, INC. | $71.14 | 2023-2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $63.64 | 2024-2025 | Voquezna |
| Lundbeck LLC | $59.39 | 2020-2023 | Vyepti |
| Exact Sciences Corporation | $48.94 | 2024 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $45.39 | 2025 | Sapien 3 Ultra Resilia |
| Hologic Sales and Service, LLC | $37.78 | 2021-2025 | Thinprep 2000 Processor, Aptima |
| Regeneron Healthcare Solutions, INC. | $37.22 | 2024-2025 | Evkeeza |
| Noven Therapeutics, LLC | $37.08 | 2023-2024 | Xelstrym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.63 | 2024-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $33.49 | 2023-2024 | Trintellix |
| Exeltis, USA INC. | $29.84 | 2024 | Slynd |
| Endo Pharmaceuticals INC. | $29.25 | 2021 | |
| Idorsia Pharmaceuticals US INC | $28.48 | 2023-2024 | Quviviq |
| Eisai INC. | $26.99 | 2025 | |
| Impel Pharmaceuticals INC. | $24.31 | 2022 | |
| Abbott Laboratories | $23.71 | 2025 | Freestyle Libre 3 |
| Myriad Women'S Health, INC. | $22.08 | 2023 | Myrisk |
| Almatica Pharma LLC | $19.85 | 2025 | Teriparatide, Loreev Xr |
| Sunovion Pharmaceuticals INC. | $19.67 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.56 | 2024 | Rexulti |
| Medtronic, INC. | $15.48 | 2022 | |
| Avion Pharmaceuticals | $15.36 | 2022 | |
| Boston Scientific Corporation | $14.69 | 2023 | Bodyguardian |
| Glaxosmithkline, LLC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Larkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.